Bridgeway Capital Management, LLC Tcr2 Therapeutics Inc. Transaction History

Bridgeway Capital Management, LLC

  • $4.44 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$0.83 - $1.44 $41,500 - $72,000
50,000 Added 37.93%
181,810 $181,000
Q3 2022

Nov 14, 2022
BUY
$1.86 - $3.75 $62,142 - $125,287
33,410 Added 33.95%
131,810 $237,000
Q1 2022

May 16, 2022
BUY
$2.4 - $4.71 $236,160 - $463,464
98,400 New
98,400 $272,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Bridgeway Capital Management, LLC Portfolio

Follow Bridgeway Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email